According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...

Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 ...

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

The CAAT governance board recommends transitioning from the COPD Assessment Test to the CAAT and using it for patients with ...

Many individuals with chronic obstructive pulmonary disease describe exacerbations in personal, varied terms, revealing a ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for vereki ...

Around the world, several diseases are spreading quickly and, if left unchecked, can create serious issues. In particular, ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Background Antimicrobial resistance (AMR) is a growing global health crisis and is particularly relevant to people living ...

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder impacting small pulmonary arteries, leading to increased vascular resistance and heart failure. The latest report forecasts ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...